Indeed, the success of SGLT2 inhibitors across the ejection-fraction spectrum in trials such as DAPA-HF (hazard ratio (HR) = 0.74; 95% CI: 0.65–0.85) [3] and EMPEROR-Preserved (HR = 0.83; 95% CI: 0.71–0.98) [44] underscores the feasibility of broad-based, phenotype-stratified interventions. This evidence concerns the gene SLC5A2 and hydrops fetalis.